Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

23 December 2021

Alphamab Oncology Announced First Patient Dosed in the U.S. in A Phase II Pivotal Clinical Study of KN046 study to evaluate efficacy, safety and tolerability of KN046 in subjects with advanced thymic carcinoma.
21 December 2021

CSCO Tumor Immunotherapy Summit & Envafolimab China Launch Meeting Held top experts in the national oncology clinical community discussed the clinical value of immunotherapy, the efficacy and safety of Envafolimab.
16 December 2021

New Option for 30-second Dosing! First Prescriptions for the World's First Subcutaneously injected PD-L1 antibody! the first batch of prescriptions for the world's first subcutaneously injected PD-L1 antibody Envafolimab has been implemented across the country.
10 December 2021

Press Conference on the Launch of Envafolimab, the World's First Subcutaneously Injected PD-L1 Antibody providing a new treatment option for cancer patients in China
09 December 2021

Posters Highlighting clinical data of KN026 presented at SABCS 2021 two posters highlighting data from two clinical study of the anti-HER2 bispecific antibody KN026 were presented at the SABCS 2021.
03 December 2021

Envafolimab, The World’s First Subcutaneously Injected PD-L1 Antibody Approved, is Shipped Nationwide! start a new era of 30-second dosing for making cancer manageable and curable.
26 November 2021

Envafolimab, The World’s First Subcutaneously Injected PD-L1 Antibody Approved by NMPA! Alphamab Oncology Partners with 3DMed and Simcere to Innovate Immunotherapy Envafolimab is the world's first and only subcutaneously injected PD- L1
24 November 2021

IND Application for Phase 3 Registration Study of KN046 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer Was Approved by CDE We look forward to bringing new treatment options to address the urgent unmet clinical needs.
23 November 2021

Results of KN046 Combined with KN026 in the Treatment of Patients with Metastatic HER2-positive Breast Cancer Will be Presented in SABCS 2021 Preliminary Safety and Efficacy Results of KN046 in combination with KN026 in Patients with Metastatic HER2-positive Breast Cancer
03 November 2021

Alphamab Oncology Appoints Mr. Jing Han as Chief Commercial Officer Mr. Han will be responsible for the company's commercialization strategy and execution, and report to Dr. Ting Xu, Chairman & CEO of Alphamab Oncology.

6 7 8 9 10 11 12